Titre
Current Status and Challenges of Vaccination Therapy for Glioblastoma.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Hosseinalizadeh, H.
Auteure/Auteur
Rahmati, M.
Auteure/Auteur
Ebrahimi, A.
Auteure/Auteur
O'Connor, R.S.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
1538-8514
Statut éditorial
Publié
Date de publication
2023-04-03
Volume
22
Numéro
4
Première page
435
Dernière page/numéro d’article
446
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal Article ; Research Support, N.I.H., Extramural
Publication Status: ppublish
Publication Status: ppublish
Résumé
Glioblastoma (GBM), also known as grade IV astrocytoma, is the most common and deadly type of central nervous system malignancy in adults. Despite significant breakthroughs in current GBM treatments such as surgery, radiotherapy, and chemotherapy, the prognosis for late-stage glioblastoma remains bleak due to tumor recurrence following surgical resection. The poor prognosis highlights the evident and pressing need for more efficient and targeted treatment. Vaccination has successfully treated patients with advanced colorectal and lung cancer. Therefore, the potential value of using tumor vaccines in treating glioblastoma is increasingly discussed as a monotherapy or in combination with other cellular immunotherapies. Cancer vaccination includes both passive administration of monoclonal antibodies and active vaccination procedures to activate, boost, or bias antitumor immunity against cancer cells. This article focuses on active immunotherapy with peptide, genetic (DNA, mRNA), and cell-based vaccines in treating GBM and reviews the various treatment approaches currently being tested. Although the ease of synthesis, relative safety, and ability to elicit tumor-specific immune responses have made these vaccines an invaluable tool for cancer treatment, more extensive cohort studies and better guidelines are needed to improve the efficacy of these vaccines in anti-GBM therapy.
PID Serval
serval:BIB_3BEA2EC65D37
PMID
Date de création
2023-03-06T13:57:26.785Z
Date de création dans IRIS
2025-05-20T16:30:34Z